Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 8Recruiting 7Suspended 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 1

Interventions

pembrolizumab 21Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Radiotherapy 10Doxorubicin 10Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Injections 7Etoposide 7Leucovorin 6Ipilimumab 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Radiosurgery 5Prednisone 5Pemetrexed 5Methotrexate 5Dexamethasone 5Cetuximab 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × prednylidene × 30 days × Clear all
NCT02883049 2026-06-02

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

National Cancer Institute (NCI)

Phase 3 Completed
5,949 enrolled 28 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡